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FoxO3 regulates the transcription of autophagy-related genes that induce mitophagy in muscle wasting. In
this issue of Cell Metabolism, Lokireddy et al. (2012) now show that the mitochondrial ubiquitin protein ligase
1 (Mul1) polyubiquitinates the mitochondrial fusion protein Mfn2 and is necessary for FoxO3- and lysosomal-
dependent mitophagy in muscle atrophy.Free amino acids are not stored in the
body. Instead, tissue proteins can be
mobilized by enhanced proteolysis to
generate high amounts of these precur-
sors of protein synthesis and other
molecules like purines and pyrimidines.
Skeletal muscle comprises about 40% of
whole-body protein, and this reservoir is
mobilized into free amino acids under
a number of wasting conditions that
include deficient protein or energy intake
(starvation), reduced physical activity or
bedrest, and numerous pathological
states. More importantly, muscle wasting
is observed in diseases that are highly
prevalent both in Western and developing
countries and are responsible for high
rates of mortality. These include—but
are not limited to—the majority of
advanced cancers (Fearon et al., 2012),
cardiovascular diseases, chronic obstruc-
tive pulmonary disease, diabetes, and
renal failure. Short-term wasting is highly
beneficial: free amino acids arising from
the enhanced breakdown of muscle
proteins are mostly used to provide
energy by direct oxidation and neogluco-
genesis. Amino acids are also used for the
immune response and for preserving
protein synthesis in obligatory working
organs (heart, brain, diaphragm, etc.). By
contrast, prolonged wasting is a vicious
cycle resulting in a debilitating syndrome
that comprises loss of strength and weak-
ness, decreased ability to recover,
impaired efficiency of treatments, and
ultimately death. Therefore, under-
standing the mechanisms responsible
for muscle wasting is critical for both
reducing health care costs and improving
survival. In the present issue of Cell
Metabolism, Lokireddy et al. (2012)
provide insights into Mul1, a key proteinthat promotes mitophagy and skeletal
muscle loss.
In previous work, Romanello et al.
(2010) demonstrated that mitochondria,
which were suspected to trigger catabolic
signals, contribute to muscle loss and
weakness. The authors showed that
changes in mitochondrial network prevail
in atrophying muscles from fasted and
denervated mice. Expression of the mito-
chondrial fission machinery per se
induces muscle wasting in such condi-
tions by triggering organelle dysfunction
and AMPK activation (Figure 1). Con-
versely, inhibition of mitochondrial fission
inhibits muscle loss during fasting. The
authors also demonstrated that FoxO3
overexpression induces mitochondrial
disruption through activation of auto-
phagy. These data were in perfect agree-
ment with another paper (Mammucari
et al., 2007), which demonstrated that
FoxO3 induces autophagy and stimulates
expression of many autophagy (Atg)
genes in myotubes, in isolated muscle
fibers and in muscle in vivo. Furthermore,
Akt/PKB activation blocks FoxO3 activa-
tion and autophagy (Figure 1).
In this issue of Cell Metabolism, Lokir-
eddy et al. (2012) provide elegant and
strong evidence that the mitochondrial
E3 ubiquitin protein ligase 1 (Mul1, also
called MAPL, C1orf166, GIDE, MULAN,
or RNF218) is sufficient for inducing
mitophagy and muscle wasting. First
the authors examined the expression
of known regulators of mitochondrial
dynamics in catabolic myotubes. These
C2C12 cells have been either starved or
exposed to inducers of muscle wasting
such as dexamethasone (Dex, a synthetic
glucocorticoid) or recombinant human
myostatin (hMstn). They identify variousCell Metabolism 16,genes involved in mitochondrial metabo-
lism or autophagy that are upregulated
in such conditions, including Mul1. Since
Mul1 was already reported to play a role
in mitochondrial fission (Braschi et al.,
2009), the authors next verified that star-
vation- and denervation-induced muscle
atrophy also results in increased levels
of Mul1 in mouse muscle in vivo. They
then identified six putative FoxO tran-
scription factor binding sites in the
human Mul1 promoter and showed that
FoxO3 interacts physically with the Mul1
promoter. Accordingly, Mul1 promoter
activity increased in the presence of con-
stituvely active FoxO3 (ca-FoxO3) in Dex,
hMstn, and starved myotubes, and Mul1
protein levels increased in C2C12 myo-
tubes and in ca-FoxO3 starved muscles.
Importantly, Mul1 siRNA in catabolic
myoblasts and shRNA in the starved tibia-
lis anterior muscle blocked mitophagy.
The authors then identified the mitochon-
drial fusion protein Mitofusin-2 (Mfn2) as
a target of Mul1 and showed that polyubi-
quitinated Mfn2, or a high ratio of polyubi-
quitinated Mfn2/total Mfn2 (Figure 1),
correlates with mitophagy. Indeed, Mul1
siRNA increased functional mitochondria
in Dex- and hMstn-treated and starved
C2C12 myoblasts. Moreover, the propor-
tion of mitochondria internalized into
phagosomes increased in Dex- and
hMstn-treated or starved C2C12 cells,
but this adaptation was reversed by
Mul1 siRNA in the three catabolic states.
Finally, GFP-Mul1 colocalizes with RFP-
LC3, a marker of authophagy. LC3II (the
lipidated and active form of LC3)
increases in all catabolic conditions
studied in vitro, and that adaptation is
blocked by Mul1 shRNA in atrophying
muscles.November 7, 2012 ª2012 Elsevier Inc. 551
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Figure 1. FoxO3-Dependent Mitophagy
The findings of Lokireddy et al. (2012) are shown in red. Under anabolic stimuli
(in blue), Akt phosphorylates FoxO3, leading to its exclusion from the nucleus
and inhibition of transcription. Under catabolic stimuli (in yellow), dephos-
phorylated FoxO3 stimulates the transcription of MuRF-1 and MAFbx/
atrogin-1, which are involved in the proteasome-dependent breakdown of
contractile proteins and in depressed protein synthesis, respectively. Dephos-
phorylated FoxO3 also enhances the transcription of autophagy-related
genes (Atg8/LC3, Gabarapl1, Ulk2, Atg4, Atg6/Beclin1, Atg12, Bnip3, and
Bnip3l). Genes involved in mitochondria fission are shown in bold (Romanello
et al., 2010). Romanello et al. also reported that AMPK activation is crucial for
mitophagy and concluded that the mitochondrial network is an essential
amplificatory loop of themuscular atrophy program. Note that Mul1 is involved
in the downregulation of mitochondrial fusion (through Mfn2 ubiquitination)
and increased mitochondrial fission (through DRP1 sumoylation, see Braschi
et al. [2009]). Mfn2-Ubn/Mfn2 represents the ratio of polyubiquitinated
Mfn2/Mfn2. Dotted lines and ? denote hypotheses that need to be experimen-
tally addressed.
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PreviewsAltogether these data
nicely demonstrate that
Mul1 is critical for the inhibi-
tion of mitochondrial fusion
through the autophagic path-
way and for muscle wasting.
Thus, Mul1-dependent poly-
ubiquitination of Mfn2 does
not affect the breakdown of
muscle proteins per se. This
situation is analogous to
findings regarding enhanced
expression of ubiquitina-
tion and deubiquitination en-
zymes, which also prevails
in muscle wasting. The over-
expressed muscle-specific
E3 MAFbx/atrogin-1 and
deubiquitinating enzyme
USP19 were believed to be
markers of enhanced prote-
olysis but are more related
to depressed protein syn-
thesis (reviewed in Attaix
et al. [2012]). Signaling path-
ways of protein synthesis
and breakdown are thus intri-
cate and interdependent,
acting through key proteins
at their crossroads (i.e., Akt
that is activated by anabolic
stimuli, see Figure 1, or the
glucocorticoid receptor, see
Shimizu et al. [2011]). So
far, only MuRF1, another
muscle-specific E3, hasbeen shown to directly target major
contractile muscle proteins for break-
down by the ubiquitin-proteasome sys-
tem (UPS) (Clarke et al., 2007; Polge
et al., 2011).
A number of questions remain (see
Figure 1). It is not clear whether the lyso-
somal pathway also degrades key muscle
proteins in addition to its regulatory role in
mitochondrial fission and subsequent
muscle wasting. Mul1-induced mitoph-
agy was previously reported to involve
the Mul1-dependent sumoylation of the
mitochondrial fission GTPase dynamin-
related protein 1 (DRP1) (see Braschi
et al. [2009]). The respective roles of poly-
ubiquitination (this paper) and sumoyla-552 Cell Metabolism 16, November 7, 2012 ªtion of the targets of Mul1 in mitochondrial
fusion and fission thus remain to be
explored. Whether Mul1 has any direct
effect on the UPS and contributes to the
catabolic response must be further inves-
tigated. Finally, muscle wasting results
not only from a coordinate activation
of the UPS and the lysosomal pathway,
but also from the activation of the
Ca2+-dependent and caspase systems
and matrix metalloproteases (for the
latter activation in a model of immobiliza-
tion-induced atrophy, see Slimani et al.
[2012]). Therefore, a first important
goal would be to precisely identify
proteins degraded by each proteolytic
system under muscle-wasting conditions.2012 Elsevier Inc.Second, and more impor-
tantly, determining whether
all muscle proteolytic systems
are coordinately activated,
and whether activation
requires several transcription
factors or one such as
FoxO3, is a forthcoming chal-
lenge. Altogether, these ex-
periments should help the
design of new and effective
approaches to prevent or limit
muscle wasting.REFERENCES
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